Overview
Neuropathic Pain Market Data Product Overview
The Neuropathic Pain Market data product covers market sizing, historical and forecast analysis, market segmentation, regional and country-level insights, competitive analysis, key players, strategic innovations, growth drivers, restraints, and investment opportunities. The market was valued at USD 9.62 billion in 2024 and is estimated at USD 10.60 billion in 2025, with revenue projected to reach USD 17.22 billion by 2030 at a CAGR of 10.2% from 2025 to 2030. The study analyzes drug class, indication, route of administration, distribution channel, and regional markets, with geographic coverage across 28 countries. The research combines primary interviews with industry experts and secondary research from proprietary databases and industry sources, with findings presented as aggregated market analysis.
Use Cases
-
Market entry sizing: Assess market potential from USD 10.60 billion in 2025 to USD 17.22 billion by 2030, supported by country-level analysis across 28 countries.
-
Therapy and treatment evaluation: Compare antidepressants, anticonvulsants, opioids, capsaicin, and other drug classes across diabetic neuropathy, chemotherapy-induced peripheral neuropathy, postherpetic neuralgia, trigeminal neuralgia, and other indications.
-
Competitive benchmarking: Evaluate 10 profiled companies and market-share information available for 10 companies, covering pharmaceutical and biotechnology players active in neuropathic pain therapies.
-
Commercial strategy and channel assessment: Analyze oral, topical, and injectable routes alongside hospital pharmacies, drug stores and retail pharmacies, and e-commerce platforms.
Metadata
**Update Frequency: **One-time syndicated product
Data Source(s): Primary interviews + secondary research (proprietary databases, industry journals)
Original Publisher of data: Next Move Strategy Consulting
Geographic coverage: 28 countries across North America, Europe, Asia-Pacific, and Rest of the World, including Latin America, Middle East, and Africa, with country-level analysis
Time period coverage: 2024–2030
Is historical data "point-in-time": Historical figures are point-in-time market estimates as of publication; forecast years are projections
Data Set(s) Format(s): PDF / Excel
Raw or scraped data: No — syndicated analyst research
Key Fields: Market size, CAGR, historical and forecast values, drug class, indication, route of administration, distribution channel, regional and country analysis, company profiles, market share, competitive landscape, strategic innovations, growth drivers, restraints, and investment opportunities
Number of companies/brands covered: 10
Key Data Points
- USD 9.62 billion — global Neuropathic Pain Market size in 2024.
- USD 10.60 billion — estimated global market size in 2025.
- USD 17.22 billion — projected market revenue in 2030.
- 10.2% — CAGR projected from 2025 to 2030.
- 28 countries — geographic coverage, with 10 companies profiled and market-share information available for 10 companies.
Additional Information Company Fact Sheet: nextmsc.com
Pricing Information
Customized purchase options are available for this report. Subscribers should inquire for applicable licensing and purchase options. Actual pricing is provided through the AWS Data Exchange offer.
Regulatory and Compliance Information
This report is built from aggregated, publicly available, and licensed secondary sources plus expert interviews conducted on an aggregated basis. It contains no individually identifiable personal data.
Subscription Verification
AWS Data Exchange requires subscription verification on all public offers (subscribers confirm they're not in a restricted country or a covered party).
Need Help?
For questions about this product, contact info@nextmsc.com .
About Your Company
Next Move Strategy Consulting (NextMSC) is a Boston-based market research and management consulting firm producing syndicated and custom research across healthcare and life sciences and other sectors, combining primary expert interviews with secondary research from proprietary databases. Its research covers pharmaceuticals, medical technologies, therapies, diagnostics, and related healthcare markets. Learn more at nextmsc.com
Highlights
- The global Neuropathic Pain Market was valued at USD 9.62 billion in 2024 and is estimated at USD 10.60 billion in 2025. The market is projected to reach USD 17.22 billion by 2030, registering a 10.2% CAGR from 2025 to 2030, driven by chronic disease prevalence, aging populations, and healthcare investment.
- The report analyzes the Neuropathic Pain Market across 4 major segmentation dimensions: drug class, indication, route of administration, and distribution channel. It covers antidepressants, anticonvulsants, opioids, capsaicin, diabetic neuropathy, chemotherapy-induced peripheral neuropathy, oral, topical, injectable, pharmacy, and e-commerce channels.
- The study covers 28 countries and profiles 10 companies, with market-share analysis available for 10 companies. It evaluates emerging opportunities in neuromodulation, non-ablative implantable devices, targeted drug delivery, non-opioid therapies, and advanced pain-management approaches.
Details
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
Pricing
Custom pricing options
How can we make this page better?
Legal
Content disclaimer
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
NMSC_MarketResearch | All historical revisions | All future revisions | Not included | Not included |